1. Medtech Insight
  2. >>Archive

Cygnus and Panasonic Medical in X-ray alliance:

Cygnus Imaging is to have exclusive distribution rights to Panasonic Medical and Industrial Video's digital dental X-ray sensor technology in the US. Cygnus Imaging will incorporate the technology into the CygnusRay dental X-ray systems, which are designed to replace traditional X-ray film and reduce radiation exposure by up to 90%. Cygnus Imaging, a division of Zila, plans to begin sales in February 1998 at between $6,900 and $9,900 per product.

Cygnus Imaging is to have exclusive distribution rights to Panasonic Medical and Industrial Video's digital dental X-ray sensor technology in the US. Cygnus Imaging will incorporate the technology into the CygnusRay dental X-ray systems, which are designed to replace traditional X-ray film and reduce radiation exposure by up to 90%. Cygnus Imaging, a division of Zila, plans to begin sales in February 1998 at between $6,900 and $9,900 per product.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

Thena Capital’s New Fund Up And Running With £1M Investment In Plexāā’s Breast Cancer Device

 
• By Natasha Barrow

Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.

Execs On The Move: June 23–27, 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Court Orders US FDA To Return Trial Diversity Action Plan Guidance To Website

 
• By Sue Sutter

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.